Skip to content
ClinCalc Pro
Menu
Calcium Channel Blocker (Dihydropyridine)

Amlodipine 5–10mg

Brand names: Istin, Amlostin

This entry covers amlodipine used in chronic kidney disease, a long-acting dihydropyridine calcium-channel blocker for hypertension and angina that is a common add-on for blood-pressure control in CKD.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It blocks L-type calcium channels in vascular smooth muscle, producing peripheral arterial vasodilatation that lowers blood pressure with little direct effect on heart rate.

Prescribing in practice

  • Amlodipine is not removed by dialysis and needs no dose change in renal impairment, but ankle oedema is dose-related and may be mistaken for fluid overload in CKD.
  • It does not control proteinuria, so a renin-angiotensin blocker remains the preferred first-line agent where albuminuria is present, with amlodipine added for further BP control.
  • Avoid potent CYP3A4 inhibitors, which raise amlodipine levels and can cause pronounced hypotension.

Monitoring

Monitor blood pressure and review for peripheral oedema, distinguishing drug-induced ankle swelling from CKD-related fluid retention.

Counselling the patient

  • Ankle swelling is a common side effect and is not the same as needing a water tablet.
  • Take it at the same time each day; it can be taken with or without food.
  • Report flushing or marked dizziness.

Evidence & guidelines

Use of amlodipine as add-on therapy alongside renin-angiotensin blockade in CKD hypertension aligns with NICE hypertension and CKD guidance.

Reference: ALLHAT Trial (JAMA 2002); KDIGO Hypertension in CKD Guidelines 2021; NICE NG136 (Hypertension); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.